What is it?
Postural orthostatic tachycardia syndrome, or POTS, is defined by an excessive sustained heart-rate increase while upright, alongside chronic orthostatic symptoms and after other explanations are considered.
Why does it matter?
Symptoms can be disabling, and treatment is often based on managing circulation, heart rate, and specific contributors. A confirmed immune mechanism could eventually support more targeted therapies.
What did researchers find?
Small studies have reported autoantibodies and other immune differences. These findings are not consistent enough to show that autoimmunity causes POTS across patients.
Where is the science right now?
Clinical trials are evaluating immune-modifying approaches in selected participants. A trial tests whether a treatment works under defined conditions; it does not establish that the approach is effective.
Is this available to patients?
Standard symptom-management approaches are available. Immune therapies for POTS remain investigational outside other established indications.
What are the limitations?
POTS is heterogeneous. Studies are often small, biomarkers are unsettled, and positive antibodies can also appear in people without POTS.
What happens next?
Larger controlled studies need to identify reproducible biomarkers and determine whether any immune-defined subgroup benefits from targeted treatment.
Research Horizon
Updated September 25, 2026
The autoimmune idea is being tested directly now, and the first randomized results are more cautious than early case reports suggested.
| Approach | What was tested | Result | Evidence stage |
|---|---|---|---|
| How POTS is defined | 2015 Heart Rhythm Society consensus | Chronic orthostatic symptoms plus a heart rate rise of more than 30 bpm within 10 minutes of standing (40 or more for ages 12 to 19), without orthostatic hypotension | Established |
| Overall treatment evidence | 2025 systematic review: 21 randomized trials, 750 patients | Most trials were small; larger trials are needed to settle first-line treatment | Evolving evidence |
| IVIG for presumed autoimmune POTS | iSTAND: IVIG vs albumin infusions in 30 treated participants | No significant difference between groups; both improved | Tested, not supported (small trial) |
| POTS after COVID | RECOVER-AUTONOMIC: IVIG, ivabradine and coordinated non-drug care | Underway; trial design published in 2026 | Active research |
A small negative trial is not the final word, but it is a reason to be cautious about immune treatments for POTS outside a clinical trial or an established indication.
Sources
- NIH research context on infection-associated chronic illness
- New England Journal of Medicine: POTS review
- ClinicalTrials.gov: active and completed POTS studies
- 2015 Heart Rhythm Society expert consensus statement on POTS (Heart Rhythm)
- Systematic review of randomized trials in POTS (Trends in Cardiovascular Medicine, 2025)
- iSTAND: randomized trial of IVIG for autoimmune POTS (Clinical Autonomic Research, 2024)
- RECOVER-AUTONOMIC trial design (American Heart Journal, 2026)
What This Means
The immune hypothesis is scientifically plausible and actively studied. It is not yet a settled explanation or a basis for self-treatment.
What We Still Don't Know
Researchers do not know whether immune findings define a distinct subgroup, how to identify it reliably, or whether changing those findings improves symptoms.